Jump to main content Jump to sidebar

blurb.social: Discover the web

Forums

Log in
Sign up

Overview
Submissions
Comments

bmscom4434

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics - Bristol-Myers Squibb

Submitted by bmscom4434 on December 23, 2023 at 11:50 AM in business

No comments

32

SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1 - Bristol-Myers Squibb

Submitted by bmscom4434 on December 12, 2023 at 9:02 PM in business

No comments

62

Bristol Myers Squibb Reports Third Quarter Financial Results for 2023 - Bristol-Myers Squibb

Submitted by bmscom4434 on October 27, 2023 at 11:05 AM in business

No comments

31

Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics - Bristol-Myers Squibb

Submitted by bmscom4434 on October 9, 2023 at 9:22 PM in business

No comments

19

Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial - Bristol-Myers Squibb

Submitted by bmscom4434 on July 11, 2023 at 11:11 AM in business

No comments

62

bmscom4434

Registered on July 13, 2023

We love you.